400 patients will be enrolled and divided into 3 cohorts: Cohort A: patients with high risk localized prostate cancer (PC) defined as \>cT3 or PSA \> 20 ng/mL or presence of ECE or SVI at mpMRI;
Cohort B: patients with de novo metastatic hormone sensitive prostate cancer (mHSPC);
Cohort C: patients with metastatic castration resistant prostate cancer (mCRPC) progressing on a standard treatment.
Age > 18 years
Ability to understand and consent to informed consent;
Patient must be compliant with receiving a biopsy of the metastatic site (cohort C) and with FU assessments schedule
None
Cohort A: patients with high risk localized prostate cancer (PC) defined as \>cT3 or PSA \> 20 ng/mL or presence of ECE or SVI at mpMRI; Cohort B: patients with de novo metastatic hormone sensitive prostate cancer (mHSPC); Cohort C: patients with metastatic castration resistant prostate cancer (mCRPC) progressing on a standard treatment.
Cohort
Prospective
Not listed
Number, type and frequency of DDR and MMR germline/somatic alterations
Evaluation of the frequency, number and type of DDR and MMR germline/somatic alterations in the study population
Changes in PSA levels in the 3 cohorts
Evaluation of PSA levels (baseline versus follow-up) in the 3 cohorts compared with radiological assessment
Number of patient-derived preclinical models
Number of patient-derived preclinical models (primary 2D cell lines, organoids or PDXs)
Click on the lead sponsor to view all of their trials.
